Session IV of #BacktoHeart21 covering all things cardiometabolic disease occuring now!
First up, @JJheart_doc discusses SGLTI2 for T2DM and ASCVD!
@MedscapeLIVE
First up, @JJheart_doc discusses SGLTI2 for T2DM and ASCVD!
@MedscapeLIVE
Next up @busediabetes discusses GLP-1 agonists in patients with T2DM and ASVCD!
Dr. Darren McGuire discusses hypoglycemia and adverse outcomes.
> Hypoglycemia associated with higher risk of MACE and mortality
> Adverse outcomes may be reflective of frailty/disease severity rather than causal
> Hypoglycemia associated with higher risk of MACE and mortality
> Adverse outcomes may be reflective of frailty/disease severity rather than causal
@KatherineTuttl8 discusses kidney disease and cardiovascular risk and the role of SGLT2i, GLP-1 agonists, and Finerenone!
Very important overview of CV disease among women and minorities by @DrMarthaGulati
> Prevalence and relative risk of comorbidities varies among men and women
> More studies needed specific to women and diverse racial and ethnic populations
> Prevalence and relative risk of comorbidities varies among men and women
> More studies needed specific to women and diverse racial and ethnic populations
• • •
Missing some Tweet in this thread? You can try to
force a refresh
